We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




mHealth Device Identifies Heart Problems in Cancer Survivors

By HospiMedica International staff writers
Posted on 05 Jul 2018
Print article
Image: The Vivio app measuring pulse on an iPhone (Photo courtesy of Niema Pahlevan/ USC).
Image: The Vivio app measuring pulse on an iPhone (Photo courtesy of Niema Pahlevan/ USC).
A novel handheld platform can accurately detect cardiac dysfunction in childhood cancer survivors, according to a new study.

The Vivio device, developed at the California Institute of Technology (Caltech; Pasadena, USA), the University of Southern California (USC; Los Angeles, USA), and other institutions, is a handheld device that collects pulse waves and phonocardiogram data from the carotid artery and sends it wirelessly to an app on a compatible device, such as a smartphone or tablet. Using a specialized algorithm, left ventricular ejection fraction (LVEF) is calculated; an LVEF measure of less than 50% may indicate signs of abnormal heart function.

To test the accuracy of the device, researchers at the Childhood Cancer Survivorship Clinic (CCSC) at City of Hope (Duarte, CA, USA) conducted a cross-sectional study that compared LVEF using the Vivio wireless device, two-dimensional (2D) echocardiography, and gold-standard cardiac magnetic resonance (CMR) imaging in childhood cancer survivors exposed to anthracycline, who risk potential cardiac dysfunction from the exposure, which can often develop at a time when they are least engaged in long-term survivorship care.

In all, 191 consecutive cancer survivors participated in the study, with a median anthracycline dose of 225 mg/m². The researchers found that echocardiography overestimated mean LVEF by 4.9% compared with CMR, but no difference was seen between mean LVEF derived from the Vivio and CMR. Also, when compared with CMR, the detection of cardiac dysfunction via echocardiography was poor, but Vivio-based measurements had considerably better sensitivity. The study was published on June 21, 2018, in Clinical Cancer Research.

“The pediatric oncology community is becoming increasingly aware that there are new issues faced by many cancer survivors that may not manifest themselves until decades after their cancer treatment is done,” said lead author pediatric hematologist/oncologist Saro Armenian, DO, MPH, director of the CCSC. “One of these issues is a higher burden of cardiovascular disease, which can result from exposure to anthracyclines as part of their cancer treatment.”

“One possible implementation of Vivio could be for preliminary screening. If the patient's heart function is below a specific threshold as measured by Vivio, that patient could schedule an in-depth evaluation,” concluded Dr. Armenian. “Vivio could keep these survivors engaged, and help to reduce the burden of inconvenient tests for individuals with a normal heart function as determined by the device. It could also pave the way for a mobile health-based care management program for childhood cancer survivors.”

LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart with each contraction, and is usually expressed as a percentage. A normal LVEF ranges from 55-70%. An LVEF of less than 40% may confirm a diagnosis of heart failure. An LVEF of less than 35% increases the risk of an arrhythmia that can cause sudden cardiac arrest or death, and an ICD may be recommended for these patients.

Related Links:
California Institute of Technology
University of Southern California
City of Hope

New
Gold Member
X-Ray QA Meter
T3 AD Pro
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Hospital Bed
Alphalite
New
LED Examination Lamp
Clarity 50 LED

Print article

Channels

Surgical Techniques

view channel
Image: (Left) An image of a 3D-printed material implanted in vivo for 4 weeks. (Right) A photo of coral (Photo courtesy of Dr Zhidao Xia and Jesus Cobaleda)

Revolutionary Coral-Inspired Material for Bone Repair Promotes Faster Healing

Bone defects caused by fractures, tumors, and non-healing injuries are major contributors to disability worldwide. Traditionally, doctors have used either a patient’s own bone (autograft) or donor bone... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.